{"id":1489,"date":"2020-10-15T05:33:38","date_gmt":"2020-10-15T05:33:38","guid":{"rendered":"http:\/\/www.bioindiaservices.com\/bio3\/?page_id=1489"},"modified":"2022-04-13T07:56:06","modified_gmt":"2022-04-13T07:56:06","slug":"cardiovascular","status":"publish","type":"page","link":"http:\/\/www.bioindiaservices.com\/bio3\/cardiovascular\/","title":{"rendered":"Cardiovascular"},"content":{"rendered":"
\n \n
\n \n \n
\n
\n \n
\n \n
\n
\n \n \n
\n \n
\n \n
\n \n \n

Cardiovascular<\/h3>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n \n
\n \n
\n
\n \n \n
\n \n
\n \n
\n \n \n
Drug Eluting Balloons<\/h5>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n \n \n
\n \n
\n \n
\n \n \n
Cardiac Contractility Modulation (CCM) therapy<\/h5>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n \n \n
\n \n
\n \n
\n \n \n
Guidewire and Catheters<\/h5>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n \n \n
\n \n
\n \n
\n \n \n
Drug Eluting\n
Stent<\/h5>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n \n \n
\n \n
\n \n
\n \n \n
Accessories used in Coronary Procedures<\/h5>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n \n \n
\n \n
\n \n
\n \n
\n
\n \n \n
\n \n
\n \n
\n \n \n

Drug Eluting Balloons<\/h3>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n \n
\n \n
\n
\n \n \n
\n \n
\n \n
\n \n \n

Selution SLR\u2122<\/h4>\n <\/div>\n <\/div>\n
\n \n \n
\n

SELUTION\u2019s technology involves the formation of spherical micro-reservoirs made from Biodegradable Polymer intermixed with the drug. These micro-reservoirs provide controlled and sustained release of Sirolimus. The continuous manufacturing\n process for micro-reservoir formation provides millions of precisely formed, miniature drug delivery systems, each one the same in size with the same drug elution properties.<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n \n
\n \n
\n
\n \n \n
\n \n
\n \n \n
\n

The Micro-Reservoirs bind to the surface of the balloon, using MedAlliance\u2019s proprietary Cell Adherent Technology (CAT\u2122). This mixes the micro-reservoirs with amphiphatic lipids (those that contain both positive and negative ions).\n The lipids envelop the Micro-Reservoirs, ensuring that they remain on the balloon during its insertion into the artery and delivery to the lesion. As the balloon is expanded at the lesion site, the amphiphatic lipid carrier is attracted\n to negatively charged membranes in the endothelial cells, resulting in enhanced adhesion of the micro-reservoir coating.<\/p>\n

SELUTION SLR is the future generation of drug-eluting balloon technology for coronary and peripheral interventions with sustained limus release. Designed to deliver the same safety and performance as the best-in-class DES technology\n with the added benefit of \u201cleaving nothing behind\u201d. Breakthrough technology combining the proven safety and efficacy of Sirolimus with advanced MicroReservoir and Cell Adherent Technology (CAT\u2122) to deliver a sustained therapeutic\n effect;<\/p>\n <\/div>\n <\/div>\n

\n \n
    \n \n
  • \n \n
    <\/div>
    <\/path><\/svg><\/span><\/div>\n Controlled and sustained limus release for up to 90 days.<\/span><\/span>\n <\/div>\n <\/span>\n
    \n \n <\/div>\n <\/li>\n
  • \n \n
    <\/path><\/svg><\/span><\/div>\n Offering the broadest range of PTCA and PTA drug-eluting balloon catheters for coronary and peripheral indications.<\/span><\/span>\n <\/div>\n <\/span>\n
    \n \n <\/div>\n
    <\/div>\n <\/li>\n <\/ul>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
    \n
    \n \n \n
    \n \n
    \n \n
    \n
    \n \n \n \"\"\n
    <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
    \n \n \n
    \n \n
    \n \n
    \n \n
    \n
    \n \n \n
    \n \n
    \n \n
    \n \n \n

    Cardiac Contractility Modulation (CCM) Therapy<\/h3>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
    \n \n
    \n \n
    \n
    \n \n \n
    \n \n
    \n \n
    \n \n \n

    Optimizer\u00ae Smart<\/h4>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
    \n \n
    \n \n
    \n
    \n \n \n
    \n \n
    \n \n \n
    \n

    Once medications lose effectiveness and symptoms begin to reappear, you may experience declining quality of life. At this point your provider may consider a device called Optimizer\u00ae Smart that is designed to improve contraction of the\n heart, allowing more oxygen-rich blood to reach the body. The Optimizer\u00ae Smart system delivers Cardiac Contractility Modulation therapy which is a new therapeutic approach that improves quality of life for patients that are no longer\n adequately responding to medications intended to manage symptoms or slow the progression of heart failure. Extensive studies evaluating the FDA-approved therapy, and over 1,000 patients already living with Optimizer\u00ae Smart devices\n have demonstrated the device is safe and is proven to improve quality of life for suitable patients.<\/p>\n

    The Optimizer device is similar in size to a pacemaker and is implanted during a minimally invasive procedure while the patient is under light sedation. <\/span><\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n

    \n
    \n \n \n
    \n \n
    \n \n
    \n
    \n \n \n \"\"\n
    <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n
    \n \n \n
    \n \n
    \n \n
    \n \n
    \n
    \n \n \n
    \n \n
    \n \n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
    \n \n
    \n \n
    \n
    \n \n \n
    \n \n
    \n \n
    \n \n \n

    Guidewires and Catheters<\/h3>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
    \n \n
    \n \n
    \n
    \n \n \n
    \n \n
    \n \n
    \n \n \n

    Origin NC<\/h4>\n <\/div>\n <\/div>\n
    \n \n
    \n \n \n
    Origin NC is a non-compliant PTCA balloon catheter that combines high pressure tolerance and controlled compliance with an optimal crossing profile for the mostchallenging cases.<\/h5>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
    \n \n
    \n \n
    \n
    \n \n \n
    \n \n
    \n \n
      \n \n
    • \n \n
      <\/div>
      <\/path><\/svg><\/span><\/div>\n Offering a broad portfolio of sizes for all clinical situations in your daily practice, with balloon diameters ranging from 2.00 mm \u2013 5.00 mm and lengths from 8 mm \u2013 20 mm.<\/span><\/span>\n <\/div>\n <\/span>\n
      \n \n <\/div>\n <\/li>\n
    • \n \n
      <\/path><\/svg><\/span><\/div>\n Origin NC\u2019s low crossing profile ensures easy crossing, deliverability and controlled balloon expansion to optimize dilatation of challenging, heavily calcified lesions.<\/span><\/span>\n <\/div>\n <\/span>\n
      \n \n <\/div>\n <\/li>\n
    • \n \n
      <\/path><\/svg><\/span><\/div>\n Minimal balloon longitudinal growth (3%) ensures focused dilatation force on the target lesion.<\/span><\/span>\n <\/div>\n <\/span>\n
      \n \n <\/div>\n
      <\/div>\n <\/li>\n <\/ul>\n <\/div>\n<\/div>\n<\/div>\n<\/div>\n
      \n
      \n \n \n
      \n \n
      \n \n
      \n
      \n \n \n \"\"\n
      <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n<\/div>\n<\/div>\n
      \n \n
      \n \n
      \n
      \n \n \n
      \n \n
      \n \n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n<\/div>\n<\/div>\n
      \n \n \n
      \n \n
      \n \n
      \n \n
      \n
      \n \n \n
      \n \n
      \n \n
      \n \n \n

      Technical Specification<\/h3>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
      \n \n
      \n \n
      \n
      \n \n \n
      \n \n
      \n \n \n
      \n
      \n \n \n \n \n <\/colgroup>\n <\/table>\n